Signal Deals in RNAi: Could Alnylam Buy Into Arrowhead?

Plozasiran FDA Label Scenarios

Arrowhead’s China Strategy: Visirna, Sanofi & the Road to 20-in-25

ARWR August Outlook | Is Arrowhead About to Break the Silence on RAGE?

Sarepta 2.0: The RNAi Pivot That Changes Everything

Olezarsen vs. Plozasiran: The RNAi Race in FCS and SHTG

ARWR July Outlook

Could This New FDA Voucher Fast-Track Arrowhead’s Drugs?

The Drug That Could Launch a Platform

Arrowhead Pharmaceuticals: Strategy, Cash Runway, and What Comes Next

The Patent Race to Deliver RNAi

Why Big Pharma Is Betting on RNAi Again

ARO-DIMER-PA: New Class, Big Implications

The Race to Preserve Muscle: Scholar Rock vs Arrowhead in Obesity Treatment

Can a Shot to the Arm Reach the Brain?

Amgen vs. Lilly: Who Wins the Race to Lower Lp(a)?

ARO-RAGE: A Breakthrough at ATS 2025

What FENO Won't Tell us about ARO-RAGE

ARO-RAGE: Strategic Pause—Setting Up the Next Move

Arrowhead’s Earnings Call: Reality Check or Rally Cry?

Arrowhead Earnings Preview: What to Watch This Monday

Novartis x Arrowhead? The RNAi Deal That Could Reshape Cardiometabolic Pharma

Patrick Hsu on AI, Biotech, and the Future of Science

Novartis + Regulus: RNAi Expands Beyond the Liver

Arrowhead vs Alnylam vs Ionis: RNA Therapeutics Showdown (2025 Analysis)

Why is ARWR Under Pressure? Market Forces, Short Sellers & Calendar Triggers

PLOZASIRAN AND THE PAYER GAUNTLET

ARO-RAGE: What’s Really Going On With Arrowhead’s Asthma Drug?

Arrowhead’s Pulmonary Franchise: What Lies in Store?

RNAi Therapeutics for Alpha-1 Antitrypsin Deficiency: A Comparative Analysis

RNAi Explained: siRNA vs. miRNA and Their Roles in Gene Regulation

Arrowhead Pharmaceuticals: RNAi Therapies for Obesity

Investing in RNAi: Opportunities in Gene Silencing Technologies

RNAi Revolution Trailer